Ketamine tested as new hope for long COVID brain fog and exhaustion

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults aged 18-65 years diagnosed with LC and possess a documented history of positive COVID-19 diagnostic testing or a probable infection as determined by a healthcare provider. * One persistent symptom of fatigue or neurocognitive dysfunction as defined by rating their symptoms as moderate to severe on the screening form. * English as a primary language OR comprehension of English suitable to understand research staff instructions. * All participants must be eligible for MRI and will undergo MRI scans pre- and post-treatment Exclusion Criteria: Contraindications to ketamine therapy: * Current substance use disorder * Current mania or psychosis * Recent myocardial infarction or stroke (within 1 year) * Unstable cardiovascular disease (including uncontrolled high blood pressure \> 180/110 mmHg) * Uncontrolled seizure disorder * Pregnancy Additional exclusion criteria include: * Recent COVID-19 infection or reinfection within 8 weeks * Prior receipt of ketamine treatment * History of treatment resistant depression (TRD) prior to development of LC * Defined as completing a trial (2 months of treatment at highest tolerated dose) of 3 or more psychotropic medications from at least 2 classes of medications (i.e. SSRIs, SNRIs, antipsychotic medications, or mood stabilizers such as lithium, lamotrigine, Depakote, or oxcarbazepine) * Psychotropic medications used during treatment of LC will not be counted as medications used for TRD * Current severe depression or anxiety, and/or active suicidal ideation * Severe depression and anxiety defined as scoring \> 19 on PHQ-9 screening or \> 14 on GAD-7 screening. * Active suicidal ideation is defined as answering "yes" to question #9 on the PHQ-9 * History of bipolar disorder, schizophrenia, or schizoaffective disorder * History of suicide attempt or psychiatric hospitalization for any reason in the last 5 years * Current benzodiazepine or naltrexone medication use within 4 weeks of enrollment as these may decrease or block the therapeutic effect of ketamine treatment